Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis
David W. Denning(Manchester Academic Health Science Centre), Thomas F. Patterson(National Institute of Allergy and Infectious Diseases), Voravit Ratanatharathorn(University of Michigan–Ann Arbor), Donald N. Buell(Astellas Pharma (Japan)), Cornelia Becker(Johannes Gutenberg University Mainz), Nita L. Seibel(National Cancer Institute), D. Facklam(Astellas Pharma (Japan)), Kieren A. Marr(Freedom to Live), W. Lau(Astellas Pharma (Japan)), Patricia M. Flynn(St. Jude Children's Research Hospital), Jo‐Anne H. van Burik(University of Minnesota), Andrew J. Ullmann(University of Würzburg)
Cited by 294
Related Papers
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
|Clinical Infectious Diseases|2008|4.9k
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2015|4k
Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2009|3.6k
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision
|Journal of Fungi|2017|2.9k